Biphosphonate therapy in subcutaneous fat necrosis with hypercalcemia and nephrocalcinosis in the newborn

Sfaihi, Lamia; Kmiha, Sana; Aloulou, Hajer; Kamoun, Thouraya; Hachicha, M.

doi:10.1016/j.jnn.2012.02.001

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the same time, high melting point of the saturated fatty acids may cause crystallization of fat, result in adipocyte necrosis triggering a granulomatous reaction. 5 7 15 SCFN is mostly a self-limited process that resolves within weeks or months. However, this condition known to be associated with frequent metabolic complications as hypoglycemia, hypertriglyceridemia, or with hematological complications as anemia and thrombocytopenia.…”

Section: Discussionmentioning

confidence: 99%

“…Three to four doses of pamidronate 0.25–0.5 mg/kg have been found to be both effective and well tolerated in neonates. 14 15 19 Alos et al 16 reported four patients with severe hypercalcemia secondary to SCFN who received three to four doses of pamidronate (0.25–0.50 mg/kg/dose). The author suggested that pamidronate may be used as first-line treatment for severe hypercalcemia in infants with SCFN with the aim of reducing nephrocalcinosis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Neonatal Hypercalcemia Secondary to Subcutaneous Fat Necrosis Successfully Treated with Pamidronate: A Case Series and Literature Review

Samedi

Yusuf

Yee

et al. 2014

AJP Rep

View full text Add to dashboard Cite

Subcutaneous fat necrosis (SCFN) is a noninfectious panniculitis that occurs in term infants who experience significant distress in the 1st weeks of life, including hypoxic ischemic encephalopathy (HIE). Since the introduction of therapeutic hypothermia for HIE, there have been a few published case reports of SCFN, following this modality of treatment. Although, most cases of SCFN resolve spontaneously, SCFN may be associated with hypercalcemia, which may sometimes reach dangerous levels. Approaches used for the management of this potentially life-threatening condition, include hyperhydration, calciuric diuretics, corticosteroids, and in more resistant cases pamidronate, a bisphosphonate. We report our experience on the use of pamidronate in two cases of severe hypercalcemia associated with SCFN following therapeutic hypothermia for HIE. We believe that with increasing use of therapeutic hypothermia for HIE, clinicians are likely to encounter this condition more frequently.

show abstract

Section: Discussionmentioning

confidence: 99%